High‐Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases

Douglas I. Walker, Brian D. Juran, Angela C. Cheung, Erik M. Schlicht, Yongliang Liang, Megan Niedzwiecki, Nicholas F. LaRusso, Gregory J. Gores, Dean P. Jones, Gary W. Miller, Konstantinos N. Lazaridis – 25 November 2021 – Progress in development of prognostic and therapeutic options for the rare cholestatic liver diseases, primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), is hampered by limited knowledge of their pathogeneses.

Organ‐Specific Comorbidities Are Associated With Distinct Complications After Liver Transplantation for Biliary Atresia

Sarah A. Taylor, Veena Venkat, Ronen Arnon, Vani V. Gopalareddy, Philip Rosenthal, Sarah G. Anderson, Ravinder Anand, James F. Daniel, Society of Pediatric Liver Transplantation – 24 November 2021 – Although transplant outcomes for biliary atresia (BA) have improved, there are few data to predict the risk of specific posttransplant complications. We therefore defined the impact of comorbidities in BA on posttransplant outcomes.

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer Cells

Darko Castven, Carolin Czauderna, Diana Becker, Sharon Pereira, Jennifer Schmitt, Arndt Weinmann, Viral Shah, Jovana Hajduk, Friederike Keggenhoff, Harald Binder, Tobias Keck, Stefanie Heilmann‐Heimbach, Marcus A. Wörns, Snorri S. Thorgeirsson, Kai Breuhahn, Peter R. Galle, Jens U. Marquardt – 23 November 2021 – Induction of neoangiogenesis is a hallmark feature during disease progression of hepatocellular carcinoma (HCC). Antiangiogenetic compounds represent a mainstay of therapeutic approaches; however, development of chemoresistance is observed in the majority of patients.

Subscribe to